Synergistic targeting of CDK4/6 and BCL-2 pathways in estrogen receptor positive breast cancer

被引：1
|
作者：
Whittle, J. R.
Vaillant, F.
Policheni, A. N.
Liu, K.
Pal, B.
Giner, G.
Fernandez, K.
Gray, D. H.
Caldon, C. E.
Smyth, G. K.
Visvader, J. E.
Lindeman, G. J.
机构：
[1] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] Garvan Inst Med Res, Sydney, NSW, Australia
[5] Univ New South Wales, Sydney, NSW, Australia
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-PD7-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD7-07
引用
收藏
页数：2
相关论文
共 50 条
  • [21] BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?
    Symmans, F. W.
    BREAST, 2015, 24 : S12 - S12
  • [22] STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibition
    Kettner, Nicole M.
    Bui, Tuyen
    Ha, Min Jin
    Eckols, T. Kris
    Tweardy, David J.
    Meric-Bernstam, Funda
    Hunt, Kelly K.
    Tripathy, Debu
    Keyomarsi, Khandan
    CANCER RESEARCH, 2020, 80 (04)
  • [23] Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer
    Lim, Elgene
    Portman, Neil
    Alexandrou, Sarah
    Haupt, Susan
    Haupt, Ygal
    Caldon, Elizabeth
    CANCER RESEARCH, 2018, 78 (04)
  • [24] Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer
    Portman, Neil
    Milioli, Heloisa
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine
    Chia, KeeMing
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne
    Swarbrick, Alex
    Caldon, Liz
    Lim, Elgene
    CANCER RESEARCH, 2021, 81 (04)
  • [25] Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
    Piezzo, Michela
    Cocco, Stefania
    Caputo, Roberta
    Cianniello, Daniela
    Di Gioia, Germira
    Di Lauro, Vincenzo
    Fusco, Giuseppina
    Martinelli, Claudia
    Nuzzo, Francesco
    Pensabene, Matilde
    De Laurentiis, Michelino
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (18) : 1 - 23
  • [26] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Abeer J. Al-Qasem
    Carla L. Alves
    Sidse Ehmsen
    Martina Tuttolomondo
    Mikkel G. Terp
    Lene E. Johansen
    Henriette Vever
    Luna V. A. Hoeg
    Daniel Elias
    Martin Bak
    Henrik J. Ditzel
    npj Precision Oncology, 6
  • [27] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [28] Targeting CDK4/6 in patients with cancer
    Hamilton, Erika
    Infante, Jeffrey R.
    CANCER TREATMENT REVIEWS, 2016, 45 : 129 - 138
  • [29] Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers
    Pesch, Andrea M.
    Hirsh, Nicole H.
    Chandler, Benjamin C.
    Michmerhuizen, Anna R.
    Ritter, Cassandra L.
    Androsiglio, Marlie P.
    Wilder-Romans, Kari
    Liu, Meilan
    Gersch, Christina L.
    Larios, Jose M.
    Pierce, Lori J.
    Rae, James M.
    Speers, Corey W.
    CLINICAL CANCER RESEARCH, 2020, 26 (24) : 6568 - 6580
  • [30] Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma
    Che, Yuxuan
    Liu, Yang
    Li, Yijing
    McIntosh, Joseph M.
    Jordan, Alexa
    Yan, Fangfang
    Wang, Wei
    Nie, Lei
    Lee, Heng-Huan
    Jin, Jingling
    Yao, Yixin
    Zhao, Zhongming
    Jiang, Vivian Changying
    Wang, Michael
    BLOOD ADVANCES, 2023, 7 (14) : 3361 - 3365
12345